Dianthus Therapeutics | MGTA - Ebitda

Aktienkurs
86.16
Täglich Wechseln
0.82 0.96%
Monatlich
-7.26%
Jährlich
337.58%
Q2 Prognose
84.43




Ebitda Veränderung Datum
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Alaunos Therapeutics USD -21.02M 1.33M 2021-03
Avita Medical AUD -9.69M 12.21M 2025-12
Celltrion KRW 17.79B 356.77B 2025-12
Cspc Pharmaceutical CNY 2.19B 21.88M 2024-12
Deva Holding AS TRY 882.9M 201.7M 2023-09
Dianthus Therapeutics USD -40.19M 5.36M 2025-09
Divis Laboratories Ltd INR 8.9B 20M 2025-12
IQVIA Holdings USD 932M 114M 2026-03
Kangmei Pharma CNY 17.3M 20.56M 2025-06
Knight Therapeutics CAD 24.45M 3.46M 2025-12
Laboratorios Farma EUR 34.94M 102.95M 2025-06
Malin Corporation EUR -1.1M 200K 2024-12
Medical Developments International AUD 1.78M 3.78M 2024-12
Moderna USD -790M 582M 2025-12
Neuren Pharmaceuticals AUD 11.14M 165.56M 2025-12
Organigram Holdings CAD 5.26M 884K 2025-12
Organon & Co USD 415M 32M 2026-03
Pharma Mar EUR 2.71M 42.25M 2026-03
Qiagen NV USD 249.69M 56.53M 2025-12
Revvity USD 272.91M 24M 2026-03
Sartorius EUR 267.3M 10.1M 2026-03
Sino Biopharmaceutical CNY 2.59B 1.57B 2024-12
Tectonic Therapeutic USD -21.18M 365K 2025-12
Tilray USD 8.36M 1.82M 2025-09
Viatris USD 1.05B 46.4M 2026-03
Xeris Pharmaceuticals USD 25.09M 7.67M 2025-12
Zealand Pharma A/S -727.47M 285.54M 2025-12
Zhangzhou Pientzehuang Pharmaceutical CNY 882.7M 351.1M 2026-03